ShareThis Page

Purdue Pharma to stop marketing OxyContin to doctors

Renatta Signorini
| Monday, Feb. 12, 2018, 8:12 a.m.
OxyContin, an opioid painkiller.
OxyContin, an opioid painkiller.

Purdue Pharma, maker of prescription pain pill OxyContin, will no longer promote their products to doctors, the company told employees according to several news outlets .

OxyContin is an opioid pain reliever that contains oxycodone, which was the top drug that contributed to fatal overdoses in Westmoreland County in 2009, 2010 and 2011, according to a Tribune-Review report in December.

The move comes as numerous lawsuits have been filed against Purdue Pharma and other drug makers across the country, including in Westmoreland County , as a result of a nationwide drug epidemic. The company's practices are under investigation by Pennsylvania's attorney general. Purdue Pharma told Bloomberg and other news agencies in a statement that it would “no longer be promoting opioids to prescribers,” the outlet reported. OxyContin sales generated $1.8 billion last year, according to Symphony Health Solutions data.Prescriptions of all opioids have decreased in Allegheny and Westmoreland counties over the last year, according to a report from the Tribune-Review based on data from the state Department of Health. Renatta Signorini is a Tribune-Review staff writer. Reach her at 724-837-5374, or via Twitter @byrenatta.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.

click me